Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06313593 · ClinicalTrials.gov registry record · Phase 1

A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms

A Phase 1 study of Myeloproliferative Neoplasms, sponsored by Incyte Corporation.

Recruiting
Registry status
Phase 1
Development phase
186
Enrollment target
20
Study locations

NCT06313593 is a Phase 1 study of Myeloproliferative Neoplasms that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 186 participants, above the 128-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (45% higher). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06313593, a Phase 1 study of Myeloproliferative Neoplasms, is actively recruiting participants, sponsored by Incyte Corporation.

RECRUITING
Registry status
Phase 1
Development phase
186 participants
Enrollment target
20
Study locations

Study Summary

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Conditions Studied

Myeloproliferative Neoplasms

Interventions

  • DRUG Standard disease-directed therapy
  • DRUG INCB160058

Study Locations (20)

New York

  • Cornell Medical Center - New York
  • Icahn School of Medicine At Mount Sinai - New York
  • Sloan Kettering Institute For Cancer Research - New York

Other

  • Hospital Saint Louis - Paris
  • Institut Gustave Roussy - Villejuif
  • University Medical Center Rwth Aachen - Aachen

Quebec

  • Hopital Maisonneuve-Rosemont, Montreal, Qc - Montreal
  • McGill University Jewish General Hospital - Montreal

Alabama

  • The University of Alabama At Birmingham - Birmingham

California

  • Stanford University - Palo Alto

Florida

  • Moffitt Cancer Center - Tampa

Illinois

  • Northwestern University - Chicago

Kansas

  • The University of Kansas Cancer Center Kucc University of Kansas Clinical Research Center - Fairway

Trial Details

FieldValue
Enrollment Target 186 participants
Start Date 2024-08-08
Est. Completion 2028-10-09
Phase Phase 1

Sponsor

Incyte Corporation

239 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06313593

The ClinicalTrials.gov registry entry for NCT06313593 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 186 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 128-participant average among 8 other Myeloproliferative Neoplasms trials with a reported enrollment target (45% higher). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Myeloproliferative Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Standard disease-directed therapy is the first listed.

NCT06313593 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, Other, Quebec.

Frequently Asked Questions

What is clinical trial NCT06313593 about?

NCT06313593 is a clinical study titled "A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms". This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

What is the current status of trial NCT06313593?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 186 participants. The study started on 2024-08-08. Estimated completion is 2028-10-09.

What conditions does trial NCT06313593 study?

This clinical trial studies the following conditions: Myeloproliferative Neoplasms.

What interventions are being tested in trial NCT06313593?

The interventions under investigation include: Standard disease-directed therapy (DRUG), INCB160058 (DRUG).

Who is sponsoring clinical trial NCT06313593?

This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06313593 being conducted?

This trial has 20 study locations across Alabama, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Myeloproliferative Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Myeloproliferative Neoplasms

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.